Information Provided By:
Fly News Breaks for March 2, 2020
PEN, NVCR, JNJ, COO, BDX, BAX
Mar 2, 2020 | 07:52 EDT
In light of the recent market selloff from coronavirus fears, Wells Fargo analyst Larry Biegelsen reviewed his coverage universe to identify MedTech names that he believes will be most immune to a wider spread of the disease around the world. The criteria he used to determine which names would likely be most resilient included exposure to China; patients' ability to defer procedures; product availability via channel outside of a hospital; near-term catalysts; and potential increased demand for certain products due to coronavirus. The names Biegelsen believe are best positioned to weather a wider spread of coronavirus are Baxter (BAX), Becton Dickinson (BDX), Cooper Companies (COO), Johnson & Johnson (JNJ), Novocure (NVCR), and Penumbra (PEN).
News For BAX;BDX;COO;JNJ;NVCR;PEN From the Last 2 Days
BAX
Sep 21, 2021 | 13:43 EDT
Raymond James analyst Jayson Bedford resumed coverage of Baxter (BAX) with an Outperform rating and $93 price target. He blames a slowdown in gross margin improvement and slower revenue growth for relative stock price underperformance, but views the Hill-Rom (HRC) deal as "opportunistic" and sees revenue growth and accretion tied to the deal making Baxter "a far more interesting story," Bedford tells investors. The deal to buy Hill-Rom gives him more confidence that Baxter can grow revenue at about 5% pro-forma and will have "visible 10%+ EPS growth," added Bedford.
JNJ
Sep 21, 2021 | 12:04 EDT
Get caught up quickly on the top news and calls moving stocks with these Top Fives, as compiled by the editors of The Fly.  1... To see the rest of the story go to thefly.com. See Story Here